Biomind reports positive data from Phase II depression trial

Biomind Labs has reported positive data from part I of its Phase II clinical trial analysing its new drug candidate, BMND01, for treatment-resistant depression (TRD).

The open-label, ascending dose trial analysed the safety and tolerability of the drug candidate and protocol in 30 healthy subjects.